In this regard, one might be tempted to speculate that analogs of CXB that are devoid of COX-2-inhibitory ability, yet maintain antitumor potency, might potentially be superior for certain cancer therapeutic purposes [27]. This evidence concerns the gene PTGS2 and cancer.